Investigational new drugsHumansCarcinomaNon-Small-Cell LungMaleFemale
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.
Yasuhiro Mihashi, Kiyohide Komuta, Akihiro Tsukaguchi, Reiko Inada, Atsushi Yanagisawa, Yuhei Shimizu, Ken Yamamoto, Satoshi Tanaka, Naoko Katsurada, Takeshi Nakatani, Yuki Takeyasu, Taiichiro Otsuki, Satoshi Tetsumoto, Akihiro Tamiya, Takayuki Shiroyama
Published: 202510.1007/s10637-025-01593-w
Abstract
BACKGROUND: Selpercatinib is the current standard of care for patients with recurrent or advanced RET fusion-positive non-small cell lung cancer (RET-NSCLC). However, real-world data on selpercatinib for RET-NSCLC are extremely limited, particularly…
Preview only. Read the full abstract at the source